GUTS Fractyl Health (GUTS) Q2 FY26 earnings call
Fractyl Health reported strong one-year data for its Revita procedure, showing durable weight maintenance post-GLP-1 discontinuation with a favorable safety profile. The company is on track for key clinical and regulatory milestones for Revita in Q4 2026 and Q1 2027, while also advancing its Rejuva gene therapy platform. Management emphasized a disciplined capital strategy, with existing funds supporting operations beyond the pivotal data readout, and is preparing for commercialization with a targeted center of excellence model.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.